Search for a research project
Other search option(s)
140 Result(s)
Funded by an IRDiRC member = 
Research projects
BELGIUM
VLAAMS BRABANT
LEUVEN
Identification of defects in oligodendrocytes (OL) in familial and sporadic ALS and creation of an all human OL-neuron coculture system for screens of novel drugs that correct OL defects
University Hospitals Leuven - Gasthuisberg
Stem Cell Biology and Embryology
BELGIUM
VLAAMS BRABANT
LEUVEN
Translational research on the role of ephrin system in the pathogenesis of amyotrophic lateral sclerosis
University Hospitals Leuven - Gasthuisberg
NMRC UZLeuven
BELGIUM
VLAAMS BRABANT
LEUVEN
Preclinical testing of histone deacetylase 6 (HDAC6) inhibitors in a FUS mouse model of amyotrophic lateral sclerosis (ALS)
University Hospitals Leuven - Gasthuisberg
Laboratory of Neurobiology
CANADA
Alberta
EDMONTON
MRI biomarkers in ALS
University of Alberta
Department of Medicine, Division of Neurology
CANADA
Alberta
EDMONTON
Promoting protection of functionally intact motor units in amyotrophic lateral sclerosis (ALS).
University of Alberta
Faculty of Physical Education and Recreation
CANADA
Colombie-Britannique
VANCOUVER
Computation and theory to predict structures and mechanisms for protein misfolding in amyotrophic lateral sclerosis
University of British Columbia
Department of Physics and Astronomy
CANADA
Ontario
OTTAWA
Loss of VAPB Function in Amyotrophic Lateral Sclerosis-8 (ALS8)
Ottawa Hospital Research Institute
Neuroscience
CANADA
Ontario
TORONTO
The TAR DNA-Binding Protein (TDP-43) and Amyotrophic Lateral Sclerosis
University of Toronto
Centre for Research in Neurodegenerative Disease
CANADA
Ontario
WATERLOO
Folding and aggregation of ALS-associated mutant superoxide dismutases
University of Waterloo
Department of Chemistry
CANADA
Québec
MONTRÉAL
Synaptic targets for therapeutic protection of motor function in a genetic model of ALS
Centre Hospitalier de l'Université de Montréal
Centre of Excellence in Neuromics of Université de Montréal (CENUM)
CANADA
Québec
MONTRÉAL
Regeneration of motor neurons controlling movement and respiration from embryonic stem cells
Montreal Neurological Institute and Hospital
McGill University
CANADA
Québec
MONTRÉAL
Regulation of motor neuron identity and circuit development
Montreal Neurological Institute and Hospital
McGill University
FINLAND
Finland
HELSINKI
CDNF and MANF in genetic models of ALS
Biocenter 1, University of Helsinki
Institute of Biotechnology
FRANCE
AUVERGNE-RHONE-ALPES
CLERMONT-FERRAND
Study of Mitochondrial Functions and Oxidative Stress in ALS Patients
CHU de Clermont-Ferrand - Hôpital d'Estaing
Service d'hépatologie gastro-entérologie
FRANCE
AUVERGNE-RHONE-ALPES
GRENOBLE
First study in France searching a link between Amyotrophic Lateral Sclerosis (ALS) and beta-N-methylamino-L-alanine (BMAA) cyanotoxin
CHU de Grenoble site Nord - Hôpital Albert Michallon
Centre de Références des Maladies Neuromusculaires (CRMN)
FRANCE
CENTRE-VAL DE LOIRE
ORLÉANS
Evaluation of new inhibitors of LIMK1 and LIMK2, kinases of the Rho-GTPase pathway, in a mouse model of amyotrophic lateral sclerosis
UPR4301 Centre de biophysique moléculaire (CBM)
Equipe signalisation cellulaire et neurofibromatose
FRANCE
CENTRE-VAL DE LOIRE
TOURS
SUMOylation and aggregation of TDP43: roles in the pathophysiology of amyotrophic lateral sclerosis
CHRU de Tours - Hôpital Bretonneau
Laboratoire de biochimie et biologie moléculaire
FRANCE
CENTRE-VAL DE LOIRE
TOURS CEDEX 1
New therapeutic strategy in ALS based on metabolic status and associated metabolic disorders
Université de Tours
Imagerie et Cerveau "Neurogénétique et Neurométabolome" Equipe 2
FRANCE
GRAND-EST
ILLKIRCH-GRAFFENSTADEN
Therapeutic approach for Amyotrophic Lateral Sclerosis due to G4C2 expansion in C9ORF72
Institut de génétique et de biologie moléculaire et cellulaire - IGBMC
Département Médecine translationnelle et neurogénétique
FRANCE
GRAND-EST
STRASBOURG
Involvement of metabolic dysfunctions in the pathogenesis of amyotrophic lateral sclerosis
Faculté de médecine de Strasbourg - Louis Pasteur
Laboratoire de signalisations moléculaires et neurodégénérescence
FRANCE
GRAND-EST
STRASBOURG
Mechanisms of the spread of FUS proteininopathy during amyotrophic lateral sclerosis
Faculté de médecine de Strasbourg - Louis Pasteur
Mécanismes centraux et périphériques de la Neurodégénérescence - INSERM U1118
FRANCE
GRAND-EST
VANDOEUVRE LES NANCY CEDEX
Study of the functions of SMS and TDP-43, whose defectslead to Spinal Muscular Atrophy and Amyotrophic Lateral Sclérosis respectively, in the biogenesis of the small Cajal body-specific and small nucleolar RNPs
Institut des sciences de l'ingénierie et des systèmes
UMR7365 Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA)
FRANCE
HAUTS-DE-FRANCE
LILLE
GIFT-ALS: Growth factor preparations From plaTelets-Amyotrophic Lateral Sclerosis
CHRU de Lille
Service de Pharmacologie Médicale
FRANCE
HAUTS-DE-FRANCE
LILLE
Potential role for nocturnal PtcCO2 monitoring in the close follow up of amyotrophic lateral sclerosis patients
CHRU de Lille - Hôpital Albert Calmette
Clinique de Pneumologie - Centre de compétences Maladies pulmonaires rares
FRANCE
ILE-DE-FRANCE
PARIS
Localisation and identification of causative genes for amyotrohic lateral sclerosis
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Excitabilité, synapse & pathologies associées
FRANCE
ILE-DE-FRANCE
PARIS
The issue of prenatal / preimplantation diagnosis in parentage information in neurogenetic and neuromuscular dominant diseases
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
UF de Neurogénétique Moléculaire et Cellulaire
FRANCE
ILE-DE-FRANCE
PARIS
Presymptomatic neuromuscular junction defects and compensatory mechanisms in ALS
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Unité Nerf périphérique, Sclérose Latérale Amyotrophique (SLA)
FRANCE
ILE-DE-FRANCE
PARIS
Study of the interactions between microglial cells, macrophages and neurons from three axes in an animal model of amyotrophic lateral sclerosis
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Equipe "Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives"
FRANCE
ILE-DE-FRANCE
PARIS
Implication of peripheral macrophages in ALS
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Equipe "Bases moléculaires, physiopathologie et traitement des maladies neurodégénératives"
FRANCE
ILE-DE-FRANCE
PARIS
Involvement of metabolic dysfunctions in the pathogenesis of amyotrophic lateral sclerosis
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Département de Neurologie - Pôle des Maladies du Système Nerveux
FRANCE
ILE-DE-FRANCE
PARIS
From Movement Preparation to Gait Execution in ALS: : Combined Neurophysiological and Neuroimaging Approaches - FR
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Groupement hospitalier universitaire Pitié-Salpétrière
FRANCE
ILE-DE-FRANCE
PARIS
Predict to prevent frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS)
CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
Institut du Cerveau et de la Moëlle épinière - INSERM U1127
FRANCE
ILE-DE-FRANCE
PARIS
Role of TDP-43 in ALS pathogenesis: understanding TDP-43 aggregates neurotoxicity and the role of tunneling nanotubes in their spreading
Institut Pasteur
Biologie Cellulaire et Infection - Trafic Membranaire et Pathogénèse
FRANCE
ILE-DE-FRANCE
PARIS
Peripheral macrophages as a promising target to modulate ALS disease progression
Institut de Cerveau et de la Moelle épinière
Equipe: Causes de la SLA et mécanismes de la dégénérescence mo toneuronale
FRANCE
ILE-DE-FRANCE
PARIS
New gene therapy for C9ORF72-linked ALS-FTD
Institut de Myologie
Centre de recherche en Myologie - UPMC UM76 - CNRS FRE3617 -INSERM U974
FRANCE
ILE-DE-FRANCE
PARIS
Gene hunting in familial Amyotrophic Lateral Sclerosis
Institut du Cerveau et de la Moelle épinière
Equipe « Sclérose latérale amyotrophique : causes et mécanismes de la dégénérescence des neurones moteurs »
FRANCE
ILE-DE-FRANCE
PARIS
Study of the pathological consequences of the loss of function of the C9ORF72 gene and its implication in autophagy
Institut du Cerveau et de la Moelle épinière
Traitement de la sclérose latérale amyotrophique : de la génétique au poisson zèbre
FRANCE
ILE-DE-FRANCE
PARIS
Can a spinal interneuropathy contribute to motoneuron degeneration in ALS? An electrophysiological study on patients and mouse models of ALS
Université Paris Descartes - Paris 5
Centre de Neurophysique, Physiologie et Pathologie - CNRS UMR 8119
FRANCE
ILE-DE-FRANCE
PARIS CEDEX 06
Is spinal motoneuron degeneration in ALS caused by their abnormal excitability?
Centre de Neurophysique, Physiologie et Pathologie - CNRS UMR 8119
Spinal physiology and pathophysiology
FRANCE
ILE-DE-FRANCE
POISSY
Identification and characterization of gene mutations in patients with azoospermia by maturation
Centre hospitalier intercommunal Poissy-Saint-Germain-en-Laye
Unité de Cytogénétique
FRANCE
NOUVELLE AQUITAINE
BORDEAUX
Study of the Expression of Micro-RNA as Biomarker Diagnosis and Prognosis in Amyotrophic Lateral Sclerosis- FR
CHU - Hôpitaux de Bordeaux
FRANCE
NOUVELLE AQUITAINE
BORDEAUX CEDEX
Bumetanide treatment of the early alteration of chloride homeostasis in ALS mouse spinal motoneurons
Institut de Neurosciences cognitives et intégratives d'Aquitaine INCIA
Développement des réseaux neuronaux en conditions normales et pathologiques
FRANCE
NOUVELLE AQUITAINE
LIMOGES
BMAALS: First study in France seraching a link between Amyotrophic Lateral Sclerosis and BMAA's cyanotoxin
Faculté de médecine de Limoges
Institut d'épidémiologie neurologique et de neurologie tropicale
FRANCE
NOUVELLE AQUITAINE
LIMOGES CEDEX
Population-based study to compare ALS incidence, mortality rates and phenotype between European and Hispanic populations in relation to genetic ancestral origin
Faculté des Sciences et Techniques
Institut d'Epidémiologie neurologique et de Neurologie Tropicale
FRANCE
OCCITANIE
MONTPELLIER
ALS in Herault: epidemiology ans exposure into and outside the thau cluster
CHRU de Montpellier - Hôpital Gui de Chauliac
Unité Scléroses en plaques et substances blanches
FRANCE
OCCITANIE
MONTPELLIER
FaSMALS : Common Pathogenic Pathways and Therapeutics for SMA and ALS motoneuron diseases - FR
CHU de Montpellier - Hôpital Saint-Eloi
Institut des Neurosciences de Montpellier - INSERM U1051
FRANCE
OCCITANIE
MONTPELLIER
From knowledge base of the pathogenic astrocyte-motoneuron communication in amyotrophic lateral sclerosis to therapeutic approaches
CHU de Montpellier - Hôpital Saint-Eloi
Institut des Neurosciences de Montpellier - INSERM U1051
FRANCE
OCCITANIE
MONTPELLIER CEDEX 05
thwart TDP-43-induced mitochondrial defects in amyotrophic lateral sclerosis
Mécanismes moléculaires dans les démences neurodégénératives (MMDN)
Equipe 4 : La maladie de Huntington : neurophysiopathologie de la drosophile à la souris
FRANCE
OCCITANIE
MONTPELLIER CEDEX 5
In vitro analysis of the neuromuscular junction in amyotrophic lateral sclerosis. Role of anoctamine 6
Institut des Neurosciences de Montpellier
Motricité
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
MITOTARGET: mitochondrial apoptotic pathways in neurodegenerative diseases and assessment of the effects of new small molecules (WP4)
Parc scientifique et technologiques de Luminy
Institut de Biologie du Développement de Marseille-Luminy
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
MITOTARGET: dysfonction mitochondriale dans les maladies neurodégénératives: vers de nouvelles thérapies (coordination)
Parc scientifique et technologiques de Luminy
TROPHOS SA
GERMANY
Baden-Württemberg
TÜBINGEN
Cell Biology of the FTD/ALS Associated Nuclear Splice Factor TDP-43
Hertie-Institut für klinische Hirnforschung (HIH)
Abteilung für Neurodegeneration - Funktionelle Neurogenetik
GERMANY
Baden-Württemberg
TÜBINGEN
MITOTARGET: in vivo evidence of mitochondrial-targeted therapeutics (WP5)
Institut für Medizinische Genetik und angewandte Genomik Tübingen
Institut für Medizinische Genetik und angewandte Genomik
GERMANY
Baden-Württemberg
ULM
Epidemiology of motoneuron diseases - A case-control study
Universitäts- und Rehabilitationskliniken Ulm (RKU)
Klinik für Neurologie
GERMANY
Baden-Württemberg
ULM
MULTIMONO : A multicentric approach to monocyte alterations in ALS
Universitäts- und Rehabilitationskliniken Ulm (RKU)
Klinik für Neurologie
GERMANY
Baden-Württemberg
ULM
Aggregated-TDP43: Detection of disease specific aggregates of TDP-43 in cerebrospinal fluid of ALS patients for disease specific diagnosis
Universitäts- und Rehabilitationskliniken Ulm (RKU)
Klinik für Neurologie
GERMANY
Hessen
FRANKFURT AM MAIN
MITOTARGET: Mitochondriale Membran-Eigenschaften im Prozess der Neurodegeneration und Untersuchung der Effekte von neuen kleinen Molekülen (WP2)
Johann Wolfgang Goethe-Universität Frankfurt
Pharmakologisches Institut für Naturwissenschaftler
GERMANY
Niedersachsen
GÖTTINGEN
ROCK-ALS : Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS -DE-
Universitätsmedizin Göttingen
Klinik für Neurologie
GERMANY
Nordrhein-Westfalen
AACHEN
Fly-SMALS: Common RNA-dependent pathways for motor neuron degeneration in spinocerebellar muscular atrophy and amyotrophic lateral sclerosis (coordination)
Universitätsklinikum Aachen
Klinik für Neurologie
GERMANY
Nordrhein-Westfalen
BONN
Role of PGC-1A in the evolution of amyotrophic lateral sclerosis and effects of its regulation
Universitätsklinikum Bonn
Klinik für Neurodegenerative Erkrankungen & Gerontopsychiatrie
GERMANY
Nordrhein-Westfalen
ESSEN
Nutrition and Quality of Life in Amyotrophic Lateral Sclerosis
Universitätsklinikum Essen
Klinik für Neurologie
GERMANY
Nordrhein-Westfalen
MÜNSTER
REALS: Repurposed Enoxacin for the treatment of patients with Amyotrophic Lateral Sclerosis -DE-
Max-Planck-Gesellschaft
Molecular Neurogenetics Laboratory
GERMANY
Sachsen
DRESDEN
CureALS: Stress granules and proteostasis in motor neurons: towards a mechanistic understanding of ALS (coordination)
Max Planck Institute of Molecular Cell Biology and Genetics
Forschungsgruppe Alberti
IRELAND
County Dublin
DUBLIN
Behavioral Changes in ALS: What Families and Health Care Professionals need to know
Trinity College Dublin
Research Motor Neurone - Trinity Biomedical Sciences Institute
ISRAEL
ISRAEL
TEL AVIV
ALS-degeneration: The molecular basis for neurodegeneration and muscle atrophy in ALS - IL
University of Tel-Aviv
Dept. of Physiology and Pharmacology
ITALY
LAZIO
ROMA
Sod1-linked familial amyotrophic lateral sclerosis: novel strategies to rescue mitochondrial damage in motor neurons
Centro Europeo di Ricerca sul Cervello
Laboratorio di Neurochimica
ITALY
LAZIO
ROMA
Study of the function of mitochondria in mouse models of familial amyotrophic lateral sclerosis associated with the mutations in the SOD1 gene through genetic manipulation of the P66SHC molecular pathway
Centro Europeo di Ricerca sul Cervello
Laboratorio di Neurochimica
ITALY
LAZIO
ROMA
Proposal for an integrated approach to rare diseases: a study between basic laboratory models and clinical epidemiology in amyotrophic lateral sclerosis (ALS)
ISS - Istituto Superiore di Sanità
Reparto Farmaci per la Salute del Bambino e della Donna - Dipartimento del Farmaco
ITALY
LOMBARDIA
MILANO
Mechanism of transmembrane integration of tail-anchored proteins into the endopasmic reticulum: characterization of a novel mechanism of membrane biogenesis and its implications for er physiology and pathology
Consiglio Nazionale delle Ricerche
Istituto di Neuroscienze
ITALY
LOMBARDIA
MILANO
Modulating motor neuron vulnerability using the oculomotor restricted genes IGF-2 and SYT13 for ALS therapy
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
Dipartimento di Scienze Neurologiche
ITALY
LOMBARDIA
MILANO
Preclinical studies aimed to develop target genes based therapies for the treatment of amyotrophic lateral sclerosis
Istituto di Ricerche Farmacologiche "Mario Negri"
Laboratorio di Neurobiologia Molecolare
ITALY
LOMBARDIA
MILANO
In vitro and in vivo studies on the interplay between inflammatory and excitotoxic mechanisms and on the role of p38 mitogen activated protein kinase pathway in the pathogenesis of familial amyotrophic lateral sclerosis
Istituto di Ricerche Farmacologiche "Mario Negri"
Dipartimento di Neuroscienze
ITALY
LOMBARDIA
MILANO
Novel biomarkers of amyotrophic lateral sclerosis: role in pathogenesis and possible therapeutic targets
Istituto di Ricerche Farmacologiche "Mario Negri"
Laboratorio di Proteomica Traslazionale
ITALY
LOMBARDIA
MILANO
Novel biomarkers of amyotrophic lateral sclerosis: role in pathogenesis and possible therapeutic targets
Istituto di Ricerche Farmacologiche "Mario Negri"
Laboratorio di Proteomica Traslazionale
ITALY
LOMBARDIA
PAVIA
Apoptosis of spinal cord astrocytes secondary to ALS-Linked SOD1 mutations: mechanism, relevance for motor neuron degeneration and protective pharmacological intervention.
Fondazione Salvatore Maugeri
Laboratorio di Ricerca sulle malattie Neurodegenerative
ITALY
LOMBARDIA
PAVIA
Novel therapeutic strategies for Spinal Muscular Atrophy: testing the efficacy of cell-permeable peptides in preclinical models
Fondazione Salvatore Maugeri
Laboratorio di Ricerca sulle malattie Neurodegenerative
ITALY
PIEMONTE
TORINO
Mutations in the MATR3 gene as a cause of amyotrophic lateral sclerosis (ALS)
Ospedale Molinette
Centro regionale esperto per la sclerosi laterale amiotrofica
ITALY
PIEMONTE
TORINO
Evaluation of disease onset and disease stage/severity in patients with amyotrophic lateral sclerosis using FDG-PET imaging (INSPIRED) - IT
Ospedale Molinette
Centro regionale esperto per la sclerosi laterale amiotrofica
ITALY
PUGLIA
BARI
Amyotrophic lateral sclerosis (SLA) and riboflavin responsive multiple Acyl-CoA dehydrogenase deficiency (RR-MADD)
Università degli Studi di Bari Aldo Moro
Laboratorio di Biochimica e Biologia Molecolare E.Quagliarello
ITALY
SICILIA
PALERMO
Biological and genetic variables in the pathogenesis and clinical progression of amyotrophic lateral sclerosis: identification of biomarkers
Consiglio Nazionale delle Ricerche
Laboratorio di Neuroscienze
PORTUGAL
SUL
LISBOA
Crosstalk between neurotrophic factor receptors (TrkB) and adenosine A2A receptors: implications for Amyotrophic Lateral Sclerosis (ALS).
Faculdade de Medicina da Universidade de Lisboa
Unidade de Neurociências
PORTUGAL
SUL
LISBOA
Respiratory Rehabilitation in Amyotrophic Lateral Sclerosis: clinical and biochemical impact.
Faculdade de Medicina da Universidade de Lisboa
Unidade de Neuromusculares
PORTUGAL
SUL
OEIRAS
Mechanisms of SOD1 toxic aggregation in neurodegenerative processes
Instituto de Tecnologia Química e Biológica
Protein Biochemistry Folding and Stability
SPAIN
Cataluña
BARCELONA
Identification of diagnostic biomarkers for amyotrophic lateral esclerosis
Hospital de la Santa Creu i Sant Pau
Servicio de Neurología
SPAIN
Madrid
MADRID
Relationship Between Neurological Disability and Visual Impairment in Patients With ALS or Friedreich's Ataxia - ES
Hospital General Universitario Gregorio Marañón
Servicio de Oftalmología
SPAIN
Madrid
MADRID
Multitarget chiral compounds for the treatment of neurodegenerative diseases: nicotinic ACh receptors ligands, Nrf2 inducers and antiinflammatory efect
IIS Princesa - Instituto de Investigación del Hospital de La Princesa
Área de neurotransmisión, neuroprotección farmacológica y enfermedades neurodegenerativas y neuropsiquiátricas
SPAIN
Madrid
MADRID
Potential of cannabinoids as neuroprotective agents in neurodegenerative disorders: Huntington disease, amyotrophic lateral sclerosis and spinocerebellar ataxia, types 2 and 3
Universidad Complutense de Madrid. Facultad de Medicina
Grupo de Neuroquímica de los Cannabinoides
SWEDEN
Stockholms läns landsting
STOCKHOLM
In vitro molecular mechanism of amyotrophic lateral sclerosis
Stockholm University
Department of Biochemistry and Biophysics
SWEDEN
Västerbottens läns landsting
UMEÅ
Disease mechanisms in amyotrophic lateral sclerosis and frontotemporal lobar degeneration
Umeå University
Department of Medical Biosciences
SWEDEN
Västerbottens läns landsting
UMEÅ
Studies of misfolded SOD1 in amyotrophic lateral sclerosis (ALS)
Umeå University
Department of Medical Biosciences
SWEDEN
Västerbottens läns landsting
UMEÅ
Molecular portfolio of the extraocular muscles: clues to protection in muscular disease
University Hospital of Umeå
Department of Clinical Sciences
SWEDEN
Västerbottens läns landsting
UMEÅ
Genetic factors causing sporadic and familial amyotrophic lateral sclerosis (ALS/MND) with or without dementia
University Hospital of Umeå
Department of Pharmacology and Clinical Neuroscience
UNITED KINGDOM
East Sussex
BRIGHTON
Amyotrophic Lateral Sclerosis and the DNA Damage Response
University of Sussex
School of Life Sciences
UNITED KINGDOM
Greater London
LONDON
The role of Miro and PKC signalling in axonal transport defects in amyotrophic lateral sclerosis.
Medical Research Council
Medical Research Council, Head Office
UNITED KINGDOM
Greater London
LONDON
Development of a diagnostic test for familial amyotrophic lateral sclerosis type 6 through mutation screening in FUS gene
National Hospital for Neurology and Neurosurgery
The Centre for Neuromuscular Disease
UNITED KINGDOM
Greater London
LONDON
Study the role of TDP43, a new gene mutation identified recently for amyotrophic lateral sclerosis in motor neurons
The National Hospital For Neurology and Neurosurgery
Department of Neurodegenerative Disease
UNITED KINGDOM
Greater London
LONDON
Investigating a neuronal subcellular transcriptome by the novel technique of RNA TU-tagging, in a normal and ALS-related mouse model.
The National Hospital For Neurology and Neurosurgery
UCL Institute of Neurology
UNITED KINGDOM
Oxfordshire
OXFORD
Developing The Oxford Study for Biomarkers in Motor Neuron Disease (BioMOx): Capturing pre-symptomatic events and advancing clinical translation
Le Gros Clark Building - University of Oxford
Neuroscience
UNITED KINGDOM
Oxfordshire
OXFORD
The pathophysiological role of TDP43 in amyotrophic lateral sclerosis due to C9orf72 mutations
Le Gros Clark Building - University of Oxford
Neuroscience
UNITED KINGDOM
South Yorkshire
SHEFFIELD
MITOTARGET: mitochondrial dynamics in neurodegenerative diseases and assessment of the effects of new small molecules (WP1)
Sheffield Institute of Translational Neuroscience, University of Sheffield
Department of Neuroscience
UNITED KINGDOM
South Yorkshire
SHEFFIELD
The role of Miro and PKC signalling in axonal transport defects in amyotrophic lateral sclerosis.
Sheffield Institute of Translational Neuroscience, University of Sheffield
Department of Neuroscience
UNITED KINGDOM
South Yorkshire
SHEFFIELD
MITOTARGET: mitochondrial metabolic function and oxidative stress in neurodegenerative diseases and assessment of the effects of new small molecules (WP3)
The Medical School - University of Sheffield
Academic Neurology Unit
UNITED STATES
Massachusetts
BOSTON
Misfolding of Cu/Zn superoxide dismutase by pathological FUS and TDP43: relevance to amyotrophic lateral sclerosis
Boston Children's Hospital
Division of Genetics
ITALY
VENETO
CONEGLIANO
Functional study of the Senataxin gene in Drosophila, responsible of motoneuron disease
IRCCS "E. Medea" - Polo Regionale di Conegliano
Associazione ''La Nostra Famiglia''
ITALY
VENETO
CONEGLIANO
Development of motoneuron disease models in Drosophila
IRCCS "E. Medea" - Polo Regionale di Conegliano
Associazione ''La Nostra Famiglia''
ITALY
VENETO
PADOVA
Modelling the role of Atlastin in physiology and moton neuron pathology
Università degli Studi di Padova
Dipartimento di Farmacologia
FRANCE
BOURGOGNE-FRANCHE-COMTE
STRASBOURG
Clinical and psychopathological approach of neuromuscular disease on gender identity
Université de Strasbourg
Subjectivité, lien social et modernité (EA3071)
FRANCE
ILE-DE-FRANCE
EVRY
NMD-CHIP: design, production and technical validation of candidate genes targeted chips (WP3)
Généthon
Centre de Recherche Généthon
FRANCE
ILE-DE-FRANCE
PARIS
Childbirth and parenthood in women with motor disability related to rare diseases
Fondation hospitalière Sainte-Marie
Service d'Aide à la Parentalité des Personnes en Situation de Handicap
FRANCE
ILE-DE-FRANCE
PARIS
HUMAn Neuromuscular Integrative System for drug discovery
Université Paris Descartes - Paris 5
Centre de Neurophysique, Physiologie et Pathologie - CNRS UMR 8119
UNITED KINGDOM
Greater London
LONDON
Explaining and changing adverse illness perceptions in muscle disease by a cognitive behavioural therapy technique
Guy's Hospital
Health Psychology Section, Psychology Department, Institute of Psychiatry
UNITED KINGDOM
Lothian
EDINBURGH
Genetic disorders of human brain development
Western General Hospital
MRC Human Genetics Unit
UNITED KINGDOM
Tyne & Wear
NEWCASTLE UPON TYNE
TREAT-NMD: Accelerating Treatments for Neuromuscular Diseases (coordination)
Newcastle upon Tyne Hospitals NHS Trust
Institute of Genetic Medicine
UNITED KINGDOM
Tyne & Wear
NEWCASTLE UPON TYNE
NMD-CHIP: societal aspects of the development of targeted DNA-chips for high throughput diagnosis of neuromuscular disorders (WP7)
PEALS Research Centre, Newcastle University, 4th Floor
Policy, Ethics and Life Sciences (PEALS) Research Centre
ITALY
CAMPANIA
NAPOLI
Telethon Undiagnosed Disease Program - Revised Proposal
Azienda Ospedaliera Universitaria - Seconda Università degli Studi di Napoli
Laboratorio di Genetica Medica
Multicentric Research projects
- Sunnybrook Health Sciences Centre
- Canadian ALS Research Network
- Montreal Neurological Institute and Hospital
- The Durham lab
- Faculté de médecine de Limoges
- Institut d'épidémiologie neurologique et de neurologie tropicale
- Faculté de médecine de Limoges
- Institut d'épidémiologie neurologique et de neurologie tropicale
- CHU de Montpellier - Hôpital Saint-Eloi
- Institut des Neurosciences de Montpellier - INSERM U1051
- Parc scientifique et technologiques de Luminy
- TROPHOS SA
- Universitätsmedizin Göttingen
- Klinik für Neurologie
- Universitätsklinikum Aachen
- Klinik für Neurologie
- Max Planck Institute of Molecular Cell Biology and Genetics
- Forschungsgruppe Alberti
- Arnold R. Meyer Institute of Biological Sciences, Weizmann Institute of Science
- Department of Molecular Genetics
- University of Tel-Aviv
- Dept. of Physiology and Pharmacology
- Rudolf Magnus Institute Stratenum
- Neuromuscular Disorders Group
- UMC Utrecht - Universitair Medisch Centrum Utrecht
- Polikliniek Neuromusculaire Ziekten
- Centre Médical Universitaire - CMU
- Groupe Prof. Karl-Heinz KRAUSE
- John van Geest Centre for Brain Repair
- NeuroNE
- Universitäts- und Rehabilitationskliniken Ulm (RKU)
- Klinik für Neurologie
- Faculté de médecine de Clermont-Ferrand
- Laboratoire de Génétique, Reproduction et Développement
- CHU de Marseille - Hôpital de la Timone
- Laboratoire de génétique moléculaire
- Zentrum für Neuropathologie und Prionforschung (ZNP)
- Zentrum für Neuropathologie und Prionforschung der LMU München
- Charité / Max-Delbrück-Centrum für Molekulare Medizin
- Muskelforschung mit Hochschulambulanz für Muskelkrankheiten
- Hospital Universitari de Bellvitge
- Unidad de Neuropatología
- Newcastle upon Tyne Hospitals NHS Trust
- Institute of Genetic Medicine
- University of British Columbia
- Maternal Infant Child and Youth Research Network
- IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
- Servizio Clinico di Consulenza Genetica
CANADA
Ontario
TORONTO
Canadian ALS Research Network (CALS)
CANADA
Québec
MONTRÉAL
RNA-ALS: Dysregulation of RNA in the pathogenesis of ALS
FRANCE
NOUVELLE AQUITAINE
LIMOGES
Groupe français d'étude des maladies du motoneurone
FRANCE
NOUVELLE AQUITAINE
LIMOGES
EURALS: European amyotrophic lateral sclerosis consortium
FRANCE
OCCITANIE
MONTPELLIER
FaSMALS: Common Pathogenic Pathways and Therapeutics for SMA and ALS motoneuron diseases
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
MITOTARGET: mitochondrial dysfunction in neurodegenerative diseases: towards new therapeutics
GERMANY
Niedersachsen
GÖTTINGEN
ROCK-ALS : Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS
GERMANY
Nordrhein-Westfalen
AACHEN
Fly-SMALS: Common RNA-dependent pathways for motor neuron degeneration in spinocerebellar muscular atrophy and amyotrophic lateral sclerosis (DE)
GERMANY
Sachsen
DRESDEN
CureALS: Stress granules and proteostasis in motor neurons: towards a mechanistic understanding of ALS
ISRAEL
ISRAEL
REHOVOT
REALS: Repurposed Enoxacin for the treatment of patients with Amyotrophic Lateral Sclerosis
ISRAEL
ISRAEL
TEL AVIV
ALS-degeneration: The molecular basis for neurodegeneration and muscle atrophy in ALS
NETHERLANDS
Utrecht
UTRECHT
PYRAMID: Phenotype Research for ALS modifyer discovery
NETHERLANDS
Utrecht
UTRECHT
EURO-MOTOR: European multidisciplinary ALS network identification to cure motor neuron degeneration
SWITZERLAND
Suisse Romande
GENÈVE
NEURINOX: NOX enzymes as mediators of inflammation-triggered neurodegeneration: modulating NOX enzymes as novel therapies
UNITED KINGDOM
Cambridgeshire
CAMBRIDGE
EUNEURONE: European Consortium for Research in Neurodegenerative Diseases
GERMANY
Baden-Württemberg
ULM
MND-Net: German Network for motoneuron diseases
FRANCE
AUVERGNE-RHONE-ALPES
CLERMONT-FERRAND
MYORES: European Muscle Development Network (FINISHED)
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
NMD-CHIP: development of targeted DNA-chips for high throughput diagnosis of neuromuscular disorders
GERMANY
Bayern
MÜNCHEN
BNE: BrainNet Europe II: European brain tissue bank
GERMANY
Berlin
BERLIN
EUROMUSCLENET: Europäisches Informations-Netzwerk über muskuläre Erkrankungen
SPAIN
Cataluña
L'HOSPITALET DE LLOBREGAT
CIEN: Spanish Network for Cooperative Research in Neurological diseases
UNITED KINGDOM
Tyne & Wear
NEWCASTLE UPON TYNE
TREAT-NMD: Accelerating Treatments for Neuromuscular Diseases (research)
CANADA
Colombie-Britannique
VANCOUVER
Maternal Infant Child and Youth Research Network (MICYRN)
ITALY
LAZIO
ROMA